Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
25.75
-0.40 (-1.53%)
Feb 21, 2025, 4:00 PM EST - Market closed
Castle Biosciences Revenue
Castle Biosciences had revenue of $85.78M in the quarter ending September 30, 2024, with 39.50% growth. This brings the company's revenue in the last twelve months to $311.88M, up 62.43% year-over-year. In the year 2023, Castle Biosciences had annual revenue of $219.79M with 60.38% growth.
Revenue (ttm)
$311.88M
Revenue Growth
+62.43%
P/S Ratio
2.27
Revenue / Employee
$511,275
Employees
610
Market Cap
721.19M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CSTL News
- 10 days ago - Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii® - Business Wire
- 16 days ago - Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025 - Business Wire
- 5 weeks ago - Castle's Poster on DecisionDx®-SCC Selected as a “Late Breakers” Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025 - Business Wire
- 5 weeks ago - Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results - Business Wire
- 6 weeks ago - Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett's Esophagus Test - Business Wire
- 2 months ago - Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test - Business Wire
- 2 months ago - Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences' DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma - Business Wire